ID

36607

Beschreibung

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI; ODM derived from: https://clinicaltrials.gov/show/NCT02066870

Link

https://clinicaltrials.gov/show/NCT02066870

Stichworte

Versionen (1)
  1. 26.05.19 26.05.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

26. Mai 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Non-small Cell Lung Cancer NCT02066870

Englisch

Eligibility Non-small Cell Lung Cancer NCT02066870

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed stage iiib/iv lung cancer with egfr mutation
Beschreibung

Carcinoma of lung TNM clinical staging | EGFR mutation

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0684249
UMLS CUI [1,2]
C3258246
UMLS CUI [2]
C3266992
progressed after platinum-based chemotherapy
Beschreibung

Disease Progression | Status post Chemotherapy Platinum-Based

Datentyp

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2,1]
C0231290
UMLS CUI [2,2]
C0392920
UMLS CUI [2,3]
C1514162
the last anti-tumor therapy before entering this study must be gefitinib, erlotinib or icotinib, and the duration for tumor response must be no less than 4 months, or the duration for stable disease must be no less than 6 months
Beschreibung

Cancer treatment | gefitinib | erlotinib | icotinib | Tumor Response Duration | Stable Disease Duration

Datentyp

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C1122962
UMLS CUI [3]
C1135135
UMLS CUI [4]
C2604307
UMLS CUI [5,1]
C0027651
UMLS CUI [5,2]
C1704632
UMLS CUI [5,3]
C0449238
UMLS CUI [6,1]
C0677946
UMLS CUI [6,2]
C0449238
with a measurable disease with conventional ct) according to recist criteria
Beschreibung

Measurable Disease CT

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C0040405
who performance status(ps)<= 2
Beschreibung

WHO performance status scale

Datentyp

boolean

Alias
UMLS CUI [1]
C1298650
n>=1.5×109/l, plt>=1.0×109/l,hb>=9g/dl; ast&alt should <2.5uln(without liver metastasis) or <5uln(with liver metastasis).tbil<=1.5uln.
Beschreibung

Neutrophil count | Platelet Count measurement | Hemoglobin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Secondary malignant neoplasm of liver Absent | Secondary malignant neoplasm of liver | Serum total bilirubin measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0200633
UMLS CUI [2]
C0032181
UMLS CUI [3]
C0518015
UMLS CUI [4]
C0201899
UMLS CUI [5]
C0201836
UMLS CUI [6,1]
C0494165
UMLS CUI [6,2]
C0332197
UMLS CUI [7]
C0494165
UMLS CUI [8]
C1278039
signed and dated informed consent before the start of specific protocol procedures.
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
allergic to icotinib or arsenic trioxide.
Beschreibung

Hypersensitivity Icotinib | Hypersensitivity Arsenic trioxide

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C2604307
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0052416
patients with metastatic brain tumors with symptoms.
Beschreibung

Symptoms Metastatic malignant neoplasm to brain

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C0220650
severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases.
Beschreibung

Systemic disease Severe Uncontrolled | Respiration Disorder Unstable | Heart Disease Unstable | Liver disease Unstable | Kidney Disease Unstable | Respiration Disorder Uncompensated | Heart Disease Uncompensated | Liver disease Uncompensated | Kidney Disease Uncompensated

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0442893
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C0205318
UMLS CUI [2,1]
C0035204
UMLS CUI [2,2]
C0443343
UMLS CUI [3,1]
C0018799
UMLS CUI [3,2]
C0443343
UMLS CUI [4,1]
C0023895
UMLS CUI [4,2]
C0443343
UMLS CUI [5,1]
C0022658
UMLS CUI [5,2]
C0443343
UMLS CUI [6,1]
C0035204
UMLS CUI [6,2]
C0205433
UMLS CUI [7,1]
C0018799
UMLS CUI [7,2]
C0205433
UMLS CUI [8,1]
C0023895
UMLS CUI [8,2]
C0205433
UMLS CUI [9,1]
C0022658
UMLS CUI [9,2]
C0205433
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Non-small Cell Lung Cancer NCT02066870

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Carcinoma of lung TNM clinical staging | EGFR mutation
Item
histologically or cytologically confirmed stage iiib/iv lung cancer with egfr mutation
boolean
C0684249 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C3266992 (UMLS CUI [2])
Disease Progression | Status post Chemotherapy Platinum-Based
Item
progressed after platinum-based chemotherapy
boolean
C0242656 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C1514162 (UMLS CUI [2,3])
Cancer treatment | gefitinib | erlotinib | icotinib | Tumor Response Duration | Stable Disease Duration
Item
the last anti-tumor therapy before entering this study must be gefitinib, erlotinib or icotinib, and the duration for tumor response must be no less than 4 months, or the duration for stable disease must be no less than 6 months
boolean
C0920425 (UMLS CUI [1])
C1122962 (UMLS CUI [2])
C1135135 (UMLS CUI [3])
C2604307 (UMLS CUI [4])
C0027651 (UMLS CUI [5,1])
C1704632 (UMLS CUI [5,2])
C0449238 (UMLS CUI [5,3])
C0677946 (UMLS CUI [6,1])
C0449238 (UMLS CUI [6,2])
Measurable Disease CT
Item
with a measurable disease with conventional ct) according to recist criteria
boolean
C1513041 (UMLS CUI [1,1])
C0040405 (UMLS CUI [1,2])
WHO performance status scale
Item
who performance status(ps)<= 2
boolean
C1298650 (UMLS CUI [1])
Neutrophil count | Platelet Count measurement | Hemoglobin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Secondary malignant neoplasm of liver Absent | Secondary malignant neoplasm of liver | Serum total bilirubin measurement
Item
n>=1.5×109/l, plt>=1.0×109/l,hb>=9g/dl; ast&alt should <2.5uln(without liver metastasis) or <5uln(with liver metastasis).tbil<=1.5uln.
boolean
C0200633 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
C0201899 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
C0494165 (UMLS CUI [6,1])
C0332197 (UMLS CUI [6,2])
C0494165 (UMLS CUI [7])
C1278039 (UMLS CUI [8])
Informed Consent
Item
signed and dated informed consent before the start of specific protocol procedures.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Icotinib | Hypersensitivity Arsenic trioxide
Item
allergic to icotinib or arsenic trioxide.
boolean
C0020517 (UMLS CUI [1,1])
C2604307 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0052416 (UMLS CUI [2,2])
Symptoms Metastatic malignant neoplasm to brain
Item
patients with metastatic brain tumors with symptoms.
boolean
C1457887 (UMLS CUI [1,1])
C0220650 (UMLS CUI [1,2])
Systemic disease Severe Uncontrolled | Respiration Disorder Unstable | Heart Disease Unstable | Liver disease Unstable | Kidney Disease Unstable | Respiration Disorder Uncompensated | Heart Disease Uncompensated | Liver disease Uncompensated | Kidney Disease Uncompensated
Item
severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases.
boolean
C0442893 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
C0035204 (UMLS CUI [2,1])
C0443343 (UMLS CUI [2,2])
C0018799 (UMLS CUI [3,1])
C0443343 (UMLS CUI [3,2])
C0023895 (UMLS CUI [4,1])
C0443343 (UMLS CUI [4,2])
C0022658 (UMLS CUI [5,1])
C0443343 (UMLS CUI [5,2])
C0035204 (UMLS CUI [6,1])
C0205433 (UMLS CUI [6,2])
C0018799 (UMLS CUI [7,1])
C0205433 (UMLS CUI [7,2])
C0023895 (UMLS CUI [8,1])
C0205433 (UMLS CUI [8,2])
C0022658 (UMLS CUI [9,1])
C0205433 (UMLS CUI [9,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video